**Study Results Checkmate 9ER**
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma


**Trial Design**
- 18 Countries
- 651 Patients
- 134 Trial Sites

**Objective Response Rate (ORR)**
- Nivolumab + Cabozantinib: 55.7%
- Sunitinib: 27.1%
- % of Patients with Partial or Complete Response

**Progression Free Survival (PFS)**
- Nivolumab + Cabozantinib: 16.6 Months
- Sunitinib: 8.3 Months

**Median Duration of Response**
- Nivolumab + Cabozantinib: 20.2 Months
- Sunitinib: 11.5 Months

**Complete Response**
- Nivolumab + Cabozantinib: 8.0%
- Sunitinib: 4.6%

**Stable Disease**
- Nivolumab + Cabozantinib: 32.2%
- Sunitinib: 42.1%

**Side Effects**
- Grade 3 or Grade 4
- Nivolumab + Cabozantinib: 75.3%
- Sunitinib: 70.6%

**Health-related Quality of Life**
- FKSI-19 Total score

**Disease-related symptom score**
- FKSI-19 Total score